{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T05:08:29Z","timestamp":1649135309196},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00120-011-2737-x","type":"journal-article","created":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T10:12:44Z","timestamp":1326881564000},"page":"8-14","source":"Crossref","is-referenced-by-count":2,"title":["Androgen- und \u00d6strogenbiosynthesehemmer beim kastrationsresistenten Prostatakarzinom"],"prefix":"10.1007","volume":"51","author":[{"given":"A.","family":"Omlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,20]]},"reference":[{"key":"2737_CR1","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ccr.2009.11.006","volume":"8","author":"Attard","year":"2009","unstructured":"Attard G, Cooper CS, Bono JS de (2009) Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 8:458\u2013462","journal-title":"Cancer Cell"},{"key":"2737_CR2","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1158\/0008-5472.CAN-08-4531","volume":"69","author":"Attard","year":"2009","unstructured":"Attard G, Reid AH, Olmos D, Bono JS de (2009) Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 69:4937\u20134940","journal-title":"Cancer Res"},{"key":"2737_CR3","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","volume":"28","author":"Attard","year":"2008","unstructured":"Attard G, Reid AH, Yap TA et al (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 28:4563\u20134571","journal-title":"J Clin Oncol"},{"key":"2737_CR4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0960-0760(94)90131-7","volume":"50","author":"Barrie","year":"1994","unstructured":"Barrie SE, Potter GA, Goddard PM et al (1994) Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase\/C17\u201320 lyase). J Steroid Biochem Mol Biol 50:267\u2013273","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2737_CR5","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1038\/sj.onc.1210955","volume":"27","author":"Brooke","year":"2008","unstructured":"Brooke GN, Parker MG, Bevan CL (2008) Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene 27:2941\u20132950","journal-title":"Oncogene"},{"key":"2737_CR6","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1016\/j.bmc.2007.05.046","volume":"15","author":"Bruno","year":"2007","unstructured":"Bruno RD, Njar VC (2007) Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem 15:5047\u20135060","journal-title":"Bioorg Med Chem"},{"key":"2737_CR7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","volume":"19","author":"Carver","year":"2011","unstructured":"Carver BS, Chapinski C, Wongvipat J et al (2011) Reciprocal feedback regulation of PI3\u00a0K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19:575\u2013586","journal-title":"Cancer Cell"},{"key":"2737_CR8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S1470-2045(09)70229-3","volume":"10","author":"Chen","year":"2009","unstructured":"Chen Y, Clegg NJ, Scher HI (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 10:981\u2013991","journal-title":"Lancet Oncol"},{"key":"2737_CR9","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1200\/JCO.2009.25.9259","volume":"28","author":"Danila","year":"2010","unstructured":"Danila DC, Morris MJ, Bono JS de et al (2010) Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 28:1496\u20131501","journal-title":"J Clin Oncol"},{"key":"2737_CR10","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"Bono","year":"2011","unstructured":"Bono JS de, Logothetis CJ, Molina A et al (2011) COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995\u20132005","journal-title":"N Engl J Med"},{"key":"2737_CR11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"Bono","year":"2010","unstructured":"Bono JS de, Oudard S, Ozguroglu M et al (2010) TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147\u20131154","journal-title":"Lancet"},{"key":"2737_CR12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrc2174","volume":"8","author":"Ellem","year":"2007","unstructured":"Ellem SJ, Risbridger GP (2007) Treating prostate cancer: a rationale for targeting local oestrogens. Nat Rev Cancer 8:621\u2013627","journal-title":"Nat Rev Cancer"},{"key":"2737_CR13","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1210\/jc.80.12.3494","volume":"80","author":"Elo","year":"1995","unstructured":"Elo JP, Kvist L, Leinonen K et al (1995) Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J Clin Endocrinol Metab 80:3494\u20133500","journal-title":"J Clin Endocrinol Metab"},{"key":"2737_CR14","first-page":"2","volume":"47","author":"Fizazi","year":"2011","unstructured":"Fizazi K, De Bono J, Haqq C et al (2011) Final overal survival (OS) analysis of COU-AA-301, a phase 3 study of abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) pretreated with docetaxel. Eur J Cancer 47(Suppl):2","journal-title":"Eur J Cancer"},{"key":"2737_CR15","first-page":"2861","volume":"54","author":"Gaddipati","year":"1994","unstructured":"Gaddipati JP, McLeod DG, Heidenberg HB et al (1994) Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54:2861\u20132864","journal-title":"Cancer Res"},{"key":"2737_CR16","first-page":"149","volume":"63","author":"Hara","year":"2003","unstructured":"Hara T, Miyazaki J, Araki H et al (2003) Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63:149\u2013153","journal-title":"Cancer Res"},{"key":"2737_CR17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND et al (2010) IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411\u2013422","journal-title":"N Engl J Med"},{"key":"2737_CR18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1210\/er.2004-0017","volume":"3","author":"Labrie","year":"2005","unstructured":"Labrie F, B\u00e9langer A, Luu-The V et al (2005) Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 3:361\u2013379","journal-title":"Endocr Rev"},{"key":"2737_CR19","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nm.1944","volume":"5","author":"Liu","year":"2009","unstructured":"Liu W, Laitinen S, Khan S et al (2009) Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 5:559\u2013565","journal-title":"Nat Med"},{"key":"2737_CR20","doi-asserted-by":"crossref","unstructured":"(o A) (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists\u2018 Collaborative Group. Lancet 355:1491\u20131498","DOI":"10.1016\/S0140-6736(00)02163-2"},{"key":"2737_CR21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jcb.10757","volume":"91","author":"Miyamoto","year":"2004","unstructured":"Miyamoto H, Rahman MM, Chang C (2004) Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem 91:3\u201312","journal-title":"J Cell Biochem"},{"key":"2737_CR22","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","volume":"68","author":"Montgomery","year":"2008","unstructured":"Montgomery RB, Mostaghel EA, Vessella R et al (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68:4447\u20134454","journal-title":"Cancer Res"},{"key":"2737_CR23","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","volume":"90","author":"O","year":"2004","unstructured":"O\u2019Donnell A, Judson I, Dowsett M et al (2004) Hormonal impact of the 17alpha-hydroxylase\/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90:2317\u20132325","journal-title":"Br J Cancer"},{"key":"2737_CR24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.2008.20.9288","volume":"28","author":"Dreicer","year":"2010","unstructured":"Dreicer R, Agus DB, MacVicar GR et al (2010) Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: a phase I\/II, open-label study. J Clin Oncol 28(Suppl):15","journal-title":"J Clin Oncol"},{"key":"2737_CR25","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1158\/1078-0432.CCR-10-2955","volume":"17","author":"Rathkopf","year":"2011","unstructured":"Rathkopf D, Liu G, Carducci MA et al (2011) Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clin Cancer Res 17:880\u2013887","journal-title":"Clin Cancer Res"},{"key":"2737_CR26","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/jcb.20927","volume":"98","author":"Reddy","year":"2006","unstructured":"Reddy GP, Barrack ER, Dou QP et al (2006) Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer. J Cell Biochem 98:1408\u20131423","journal-title":"J Cell Biochem"},{"key":"2737_CR27","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2009.24.6819","volume":"28","author":"Reid","year":"2010","unstructured":"Reid AH, Attard G, Danila DC et al (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28:1489\u20131495","journal-title":"J Clin Oncol"},{"key":"2737_CR28","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","volume":"28","author":"Ryan","year":"2010","unstructured":"Ryan CJ, Smith MR, Fong L et al (2010) Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 28:1481\u20131488","journal-title":"J Clin Oncol"},{"key":"2737_CR29","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","volume":"375","author":"Scher","year":"2010","unstructured":"Scher HI, Beer TM, Higano CS et al (2010) Prostate cancer foundation\/department of defense prostate cancer clinical trials consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1\u20132 study. Lancet 375:1437\u20131446","journal-title":"Lancet"},{"key":"2737_CR30","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I et al (2008) Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148\u20131159","journal-title":"J Clin Oncol"},{"key":"2737_CR31","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/jnci\/djn150","volume":"100","author":"Setlur","year":"2008","unstructured":"Setlur SR, Mertz KD, Hoshida Y et al (2008) Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 100:815\u2013825","journal-title":"J Natl Cancer Inst"},{"key":"2737_CR32","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1200\/JCO.2004.06.037","volume":"22","author":"Small","year":"2004","unstructured":"Small EJ, Halabi S, Dawson NA et al (2004) Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22:1025\u20131033","journal-title":"J Clin Oncol"},{"key":"2737_CR33","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1172\/JCI41824","volume":"120","author":"Sun","year":"2010","unstructured":"Sun S, Sprenger CC, Vessella RL et al (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120:2715\u20132730","journal-title":"J Clin Invest"},{"key":"2737_CR34","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/me.11.4.450","volume":"11","author":"Tan","year":"1997","unstructured":"Tan J, Sharief Y, Hamil KG et al (1997) Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11:450\u2013159","journal-title":"Mol Endocrinol"},{"key":"2737_CR35","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1158\/1078-0432.CCR-05-0525","volume":"11","author":"Titus","year":"2005","unstructured":"Titus MA, Schell MJ, Lih FB et al (2005) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11:4653\u20134657","journal-title":"Clin Cancer Res"},{"key":"2737_CR36","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1200\/JCO.1989.7.8.1093","volume":"8","author":"Trump","year":"1989","unstructured":"Trump DL, Havlin KH, Messing EM et al (1989) High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. J Clin Oncol 8:1093\u20131098","journal-title":"J Clin Oncol"},{"key":"2737_CR37","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1677\/ERC-08-0084","volume":"4","author":"Zhu","year":"2008","unstructured":"Zhu ML, Kyprianou N (2008) Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 4:841\u2013849","journal-title":"Endocr Relat Cancer"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-011-2737-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-011-2737-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-011-2737-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T12:55:37Z","timestamp":1561208137000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-011-2737-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["2737"],"URL":"https:\/\/doi.org\/10.1007\/s00120-011-2737-x","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}